Results 141 to 150 of about 3,056 (181)
Anatomy of a Setback: A Taxonomy of Clinical Trial Failures in Alzheimer's Disease and Strategic Lessons for the Future. [PDF]
FASEB JEmanuele E, Minoretti P.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Donanemab in Early Alzheimer’s Disease
New England Journal of Medicine, 2021A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease.We conducted a phase 2 trial of donanemab in patients with early symptomatic Alzheimer's disease who had tau and amyloid deposition on ...
Alberto Espay
exaly +5 more sources
Still grasping at straws: donanemab in Alzheimer’s disease
Expert Opinion on Investigational Drugs, 2021Alzheimer's disease is the leading cause of disability and poor health, takes a huge emotional and financial burden on family caregivers, and is costly. Donanemab (LY3002813) is a new monoclonal antibody that uniquely targets Aβ(p3-42), a pyroglutamate form of Amyloid-β (Aβ) exclusively found in plaques.The phase 2 trial of donanemab in participants ...
exaly +3 more sources
Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer’s
Expert Opinion on Drug Metabolism and ToxicologyDonanemab is a humanized monoclonal antibody that significantly reduces cerebral amyloid plaques in Alzheimer's Disease (AD). It can delay disease progression and cognitive decline, making it one of the most promising disease-modifying treatments in the current treatment landscape.This paper covers the current literature available on pharmacokinetics ...
George Grossberg
exaly +3 more sources
Brain volume loss due to donanemab
European Journal of Neurology, 2021Donanemab, an antibody directed toward an N-terminal pyroglutamate Aβ epitope, was recently tested in a phase 2 trial of early symptomatic Alzheimer's disease patients (n=257) treated for 76 weeks [1]. The antibody therapy reduced plaque load by 80%.
openaire +3 more sources
Amyloid Reduction: Donanemab Perspective
Alzheimer's & Dementia, 2023AbstractBackgroundMethodsResultConclusion
openaire +1 more source
Donanemab: An innovative solution for Alzheimer's disease?
European NeuropsychopharmacologyMuhammad Shaheer Bin Faheem
exaly +3 more sources
Drugs
Donanemab (donanemab-azbt; KisunlaTM) is an amyloid β-directed antibody developed by Eli Lilly and Company for the treatment of Alzheimer's disease. Donanemab recently received approval in the USA for the treatment of adults with early symptomatic Alzheimer's disease (patients with mild cognitive impairment or mild dementia stage of disease).
openaire +2 more sources
Donanemab (donanemab-azbt; KisunlaTM) is an amyloid β-directed antibody developed by Eli Lilly and Company for the treatment of Alzheimer's disease. Donanemab recently received approval in the USA for the treatment of adults with early symptomatic Alzheimer's disease (patients with mild cognitive impairment or mild dementia stage of disease).
openaire +2 more sources
Donanemab (Kisunla) for Alzheimer's Disease
The Medical Letter on Drugs and TherapeuticsDonanemab-azbt (Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody, has been approved by the FDA for treatment of Alzheimer’s disease (AD). The label states that the drug should only be started in patients with mild cognitive impairment (MCI) or mild dementia.
openaire +2 more sources